Skip to content
Screener

Shares (Diluted) at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
66.1M+8.4%
Alkermes logo
AlkermesALKS
173.5M+3.0%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
51.2M+4.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
63.1M+6.2%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
328.1M+1.8%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
172.9M+2.5%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$2.26B+13.1%
Enterprise value$1.83B+12.9%
P/E15.5×+4.5×
P/S2.5×-0.1×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:16 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056720
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net income$32,488$45,560
Unrealized (loss) income on investments(759)179
Comprehensive income$31,729$45,739
EARNINGS PER SHARE:
Basic$0.56$0.79
Diluted$0.55$0.78
Weighted average number of shares of common stock - basic57,819,06057,309,938
Weighted average number of shares of common stock - diluted58,776,29758,524,566

Item 1. Financial Statements

FAQ

What is Harmony Biosciences Holdings, Inc.'s shares (diluted)?
Harmony Biosciences Holdings, Inc. (HRMY) reported shares (diluted) of 58.8M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s shares (diluted) changed year-over-year?
Harmony Biosciences Holdings, Inc.'s shares (diluted) increased by 0.4% year-over-year, from 58.5M to 58.8M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), Harmony Biosciences Holdings, Inc.'s shares (diluted) has grown at a -0.0% compound annual growth rate (CAGR), from 234.3M to 234.2M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Harmony Biosciences Holdings, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude